3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Other
1
Myeloid
1
Lymphoid
1
Conditions
Lymphoma, Non-Hodgkin
2
Hodgkin Disease
2
Primary Myelofibrosis
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Myelodysplastic Syndromes
1
Multiple Myeloma
1
Mucositis
1
Leukemia, Myeloid, Acute
1
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Interventions
Cyclophosphamide
14
fludarabine phosphate
11
Cyclosporine
11
Antilymphocyte Serum
10
Mycophenolic Acid
9
ruxolitinib
8
Radiotherapy
6
Cord Blood Stem Cell Transplantation
6
Busulfan
6
fludarabine
5
Whole-Body Irradiation
5
Tacrolimus
5
Methylprednisolone
5
Azacitidine
5
Stem Cell Transplantation
4
Peripheral Blood Stem Cell Transplantation
4
Methotrexate
4
Melphalan
4
Filgrastim
4
thymoglobulin
3
parsaclisib
3
Sirolimus
3
Nivolumab
3
11-(2-pyrrolidin-1-ylethoxy)-14,19-dioxa-5,7,26-triazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene
3
abiraterone
2
Tretinoin
2
Surveys and Questionnaires
2
Sunitinib
2
Rituximab
2
Moxifloxacin
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Terminated
×
Primary Myelofibrosis
×
angiotensin I (1-7)
×
Clear all
NCT01300611
2020-12-08
USBTXA127CBT
Tarix Pharmaceuticals
Phase 1
Terminated
20 enrolled